MEDIWOUND LTD (MDWD) Stock Price, Quote, News and Overview
NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD
MDWD Quote, Performance and Key Statistics
MEDIWOUND LTD
NASDAQ:MDWD (1/24/2025, 5:44:58 PM)
After market: 19.83 0 (0%)19.83
+1.55 (+8.48%)
The current stock price of MDWD is 19.83 USD. In the past month the price increased by 12.22%. In the past year, price increased by 54.92%.
MDWD Latest News, Press Releases and Analysis
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric...
MediWound to Report Third Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time
MDWD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.62 | 390.70B | ||
| JNJ | JOHNSON & JOHNSON | 14.7 | 353.49B | ||
| MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
| PFE | PFIZER INC | 10.11 | 147.85B | ||
| SNY | SANOFI-ADR | 12.56 | 131.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
| ZTS | ZOETIS INC | 29.27 | 76.07B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 69.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B |
Related stock screener links
About MDWD
Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 100
Company Website: https://www.mediwound.com/
Investor Relations: http://ir.mediwound.com/
Phone: 97289324010
MDWD FAQ
What is the stock price of MDWD?
The current stock price of MDWD is 19.83 USD.
What is the symbol for MEDIWOUND LTD stock?
The exchange symbol of MEDIWOUND LTD is MDWD and it is listed on the Nasdaq exchange.
On which exchange is MDWD stock listed?
MDWD stock is listed on the Nasdaq exchange.
Is MDWD a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MDWD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MDWD.
Does MDWD stock pay dividends?
MDWD does not pay a dividend.
What is the Price/Earnings (PE) ratio of MDWD?
MDWD does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.9).
What is the Short Interest ratio of MDWD stock?
The outstanding short interest for MDWD is 9.74% of its float.
MDWD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD is one of the better performing stocks in the market, outperforming 88.09% of all stocks.
MDWD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. Both the profitability and financial health of MDWD have multiple concerns.
MDWD Financial Highlights
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -2.9. The EPS increased by -64.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.55% | ||
| ROE | -81.96% | ||
| Debt/Equity | 0.19 |
MDWD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to MDWD. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -332.29% and a revenue growth 8.34% for MDWD